Effect of denosumab on bone mineral density and biochemical markers of bone turnover: Six-year results of a phase 2 clinical trial

Journal article


Miller, Paul D., Wagman, Rachel B., Peacock, Munro, Lewiecki, E. Michael and Bolognese, Michael A.. (2011). Effect of denosumab on bone mineral density and biochemical markers of bone turnover: Six-year results of a phase 2 clinical trial. The Journal of Clinical Endocrinology and Metabolism. 96(2), pp. 394 - 402. https://doi.org/10.1210/jc.2010-1805
AuthorsMiller, Paul D., Wagman, Rachel B., Peacock, Munro, Lewiecki, E. Michael and Bolognese, Michael A.
Abstract

Context: This is a study extension to evaluate the efficacy and safety of long-term treatment with denosumab in postmenopausal women with low bone mass. Objective: Our objective was to describe changes in bone mineral density (BMD) and bone turnover markers as well as safety with 6 yr of denosumab treatment. Design: We conducted an ongoing 4-yr, open-label, single-arm, extension study of a dose-ranging phase 2 trial. This paper reports a 2-yr interim analysis representing up to 6 yr of continuous denosumab treatment. Setting: This multicenter study was conducted at 23 U.S. centers. Patients:Of the 262 subjects who completed the parent study, 200 enrolled in the study extension and 178 (89%) completed the first 2 yr. Intervention: All subjects received denosumab 60 mg sc every 6 months. Main Outcome Measures: We evaluated BMD at the lumbar spine, total hip, femoral neck, and one third radius; biochemical markers of bone turnover; and safety, reported as adverse events. Results: Over a period of 6 yr, continuous treatment with denosumab resulted in progressive gains in BMD in postmenopausal women with low bone mass. Reduction in bone resorption was sustained over the course of continuous treatment. Independent of past treatment and discontinuation period, subjects demonstrated responsiveness to denosumab therapy as measured by BMD and bone turnover markers. The safety profile of denosumab did not change over time. Conclusions: In this study, denosumab was well tolerated and effective through 6 yr of continuous treatment in postmenopausal women with low bone mass.

Year2011
JournalThe Journal of Clinical Endocrinology and Metabolism
Journal citation96 (2), pp. 394 - 402
PublisherThe Endocrine Society
ISSN0021-972X
Digital Object Identifier (DOI)https://doi.org/10.1210/jc.2010-1805
Page range394 - 402
Research GroupInstitute for Health and Ageing
Publisher's version
File Access Level
Controlled
Place of publicationUnited States of America
Permalink -

https://acuresearchbank.acu.edu.au/item/8q783/effect-of-denosumab-on-bone-mineral-density-and-biochemical-markers-of-bone-turnover-six-year-results-of-a-phase-2-clinical-trial

Restricted files

Publisher's version

  • 39
    total views
  • 0
    total downloads
  • 4
    views this month
  • 0
    downloads this month
These values are for the period from 19th October 2020, when this repository was created.

Export as